{"slideshow_credits": null, "snippet": "Companies spend billions of dollars on drug testing each year. And yet for a surprising number of medicines, we still don\u2019t know if they\u2019re safe or effective.", "abstract": "Op-Ed article by author Clifton Leaf highlights fact that doctors have no idea why or whether anti-cancer drug Avastin works, even after 16 years of clinical trials involving tens of thousands of patients; notes that this is the norm for clinical testing of experimental medicines and calls for a smarter system for evaluating drugs.", "section_name": "Opinion", "print_page": "1", "document_type": "article", "byline": {"person": [{"firstname": "Clifton", "role": "reported", "lastname": "LEAF", "rank": 1, "organization": ""}], "original": "By CLIFTON LEAF", "contributor": ""}, "web_url": "http://www.nytimes.com/2013/07/14/opinion/sunday/do-clinical-trials-work.html", "lead_paragraph": "Companies spend billions of dollars on drug testing each year. And yet for a surprising number of medicines, we still don\u2019t know if they\u2019re safe or effective.", "headline": {"main": "Do Clinical Trials Work?", "print_headline": "Do Clinical Trials Work?", "content_kicker": "Opinion", "kicker": "Opinion"}, "_id": "51e19c397e0d9c0839d2f9b5", "word_count": "2017", "multimedia": [{"height": 126, "url": "images/2013/07/14/sunday-review/14TRIALS/14TRIALS-thumbWide-v2.jpg", "legacy": {"wideheight": "126", "wide": "images/2013/07/14/sunday-review/14TRIALS/14TRIALS-thumbWide-v2.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 628, "url": "images/2013/07/14/sunday-review/14TRIALS/14TRIALS-articleLarge.jpg", "legacy": {"xlarge": "images/2013/07/14/sunday-review/14TRIALS/14TRIALS-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "628"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2013/07/14/sunday-review/14TRIALS/14TRIALS-thumbStandard-v2.jpg", "legacy": {"thumbnail": "images/2013/07/14/sunday-review/14TRIALS/14TRIALS-thumbStandard-v2.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2013-07-14T00:00:00Z", "source": "The New York Times", "news_desk": "OpEd", "keywords": [{"value": "Clinical Trials", "name": "subject", "is_major": "N", "rank": "1"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "2"}, {"value": "Cancer", "name": "subject", "is_major": "N", "rank": "3"}, {"value": "Avastin (Drug)", "name": "subject", "is_major": "Y", "rank": "4"}, {"value": "Genentech Inc", "name": "organizations", "is_major": "N", "rank": "5"}, {"value": "Genetics and Heredity", "name": "subject", "is_major": "N", "rank": "6"}, {"value": "Gilbert, Mark R", "name": "persons", "is_major": "N", "rank": "7"}], "blog": [], "subsection_name": "Sunday Review", "type_of_material": "Op-Ed"}